View Document Preview and Link Document Date: 2013-11-29 00:21:09 Open Document File Size: 610,11 KB Share Result on Facebook
City Helsinki / Darmstadt / Sydney / Rotterdam / / Company AEs / Merck Serono Australia Pty Ltd / Merck Serono SA / Merck KGaA / / Country Switzerland / Germany / United States / Australia / / / Event FDA Phase / / Facility Pacific Highway / / / IndustryTerm antagonist protocol / assisted reproductive technology treatment / agonist long protocol / administration using pen devices / redesigned pen device / pen injection device / conventional delivery systems / assisted reproductive technology / study protocol / pen device / demonstration devices / healthcare professional / healthcare providers / / MedicalCondition ovarian hyperstimulation syndrome / condition ovarian hyperstimulation syndrome / endometriosis / miscarriages / polycystic ovary syndrome / clinically significant systemic disease / uterine myoma requiring treatment / / MedicalTreatment embryo transfer / assisted reproductive technology / ICSI / ovulation induction / ovarian stimulation / intracytoplasmic sperm injection / oocyte retrieval / in vitro fertilization / / NaturalFeature Frenchs Forest / / Organization National Health and Medical Research Council / IVFAustralia Human Research and Ethics Committee / independent ethics committee / Nurse Unit / r-hCG administration / / Person Peter Illingworth / / / Position investigator / clinic nurse / Account Manager / Manager at IVFAustralia / nurse / / Product estradiol / GONAL-f / chorionic gonadotropin / RH090 / / ProvinceOrState New South Wales / / Region South Wales / / Technology alpha / assisted reproductive technology / study protocol / agonist long protocol / ultrasound / GnRH antagonist protocol / / SocialTag 
ORIGINAL RESEARCH Short running header: Ease of use study of the redesigned follitropin alfa pen Illingworth et al Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant huma